Reduced Emergence of the M184V/I Resistance Mutation When Antiretroviral-Naïve Subjects Use Emtricitabine Versus Lamivudine in Regimens Composed of Two NRTIs Plus the NNRTI Efavirenz

REFERENCES

• De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009;33(4):307–320.
   PubMed Web of Science ®Google Scholar
• Hui CK, Zhang HY, Bowden S, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J HepatoL 2008;48(5):714–720.
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Keeffe EB. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral HepatoL 2009;16(3):149–155.
   PubMed Web of Science ®Google Scholar
• Piliero PJ. Pharmacokinetic properties of nucleoside/ nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2004;37(Suppl 1):S2–S12.
   PubMed Web of Science ®Google Scholar
• Back DJ, Burger DM, Flexner CW, Gerber JG. The pharma-cology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing. J Acquir Immune Defic Syndr 2005;39(Suppl 1):S1–23.
   PubMed Web of Science ®Google Scholar
• Bartlett JA, Chen SS, Quinn JB. Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic over-view. HIV Clin Trials. 2007;8(4):221–226.
   PubMed Web of Science ®Google Scholar
• Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304(3):321–333.
   PubMed Web of Science ®Google Scholar
• Schinazi RE Assessment of the relative potency of emtric-itabine and lamivudine. J Acquir Immune Defic Syndr Human RetroviroL 2003;34(2):243–245.
   Google Scholar
• Feng JY, Anderson KS. Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase. Biochemistry. 1999;38(1):55–63.
   PubMed Web of Science ®Google Scholar
• Rousseau FS, Kahn JO, Thompson M, et al. Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Che-mother 2001;48(4):507–513.
   PubMed Web of Science ®Google Scholar
• Rousseau FS, Wakeford C, Mommeja-Marin H, et al. Prospective randomized trial of emtricitabine versus lami-vudine short-term monotherapy in human immunodefi-ciency virus-infected patients. J Infect Dis. 2003;188(11): 1652–1658.
   PubMed Web of Science ®Google Scholar
• Moore KHP, Barrett JE, Shaw S, et al. The pharmacoki-netics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS. 1999;13(16):2239–2250.
   PubMed Web of Science ®Google Scholar
• Wang LH, Begley J, St. Claire RL, Harris J, Wakeford C, Rousseau FS. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dos-ing for the treatment of HIV infection. AIDS Res Human Retroviruses. 2004;20(11):1173–1182.
   PubMed Web of Science ®Google Scholar
• Boucher CA, Cammack N, Schipper P, et al. High-level resistance to (-) enantiomeric 2'-deoxy-2'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1993;37(10):2231–2234.
   PubMed Web of Science ®Google Scholar
• Margot NA, Waters JM, Miller MD. In vitro human immu-nodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or aba-cavir and lamivudine. Antimicrob Agents Chemother. 2006;50(12):4087–4095.
   PubMed Web of Science ®Google Scholar
• Gao H-Q, Boyer PL, Sarafianos SG, Arnold E, Hughes SH. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J Molecular BioL 2000 ;300 (2):403–418.
   PubMed Web of Science ®Google Scholar
• McColl DJ, Chappey C, Parkin NT, Miler MD. Prevalence, genotypic assiciations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. Antivir Ther 2008;13:189–197.
   PubMed Web of Science ®Google Scholar
• Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA. 2004;292(2):180–190.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2)191–201.
   Web of Science ®Google Scholar
• Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. New Engl J Med. 2006;354(3): 251–260.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Antiretro viral Drugs Using Plasma HIV RNA Measurements - Clinical Considerations for Accelerated and Traditional Approval. Rockville, MD: Author; October 2002.
   Google Scholar
• Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phe-notypic drug susceptibility assay for human immuno-deficiency virus type 1. Antimicrob Agents Chemother. 2000;44:920–928.
   PubMed Web of Science ®Google Scholar
• Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med. 2005;13(4):125–131.
   PubMedGoogle Scholar
• Borroto-Esoda K, Waters JM, Bae AS, et al. Baseline gen-otype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. AIDS Res Hum Retroviruses. 2007;23(8):988–995.
   PubMed Web of Science ®Google Scholar
• Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibi-tors predicts virologic failure of an efavirenz-based regi-men in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008;197(6):867–870.
   PubMed Web of Science ®Google Scholar
• Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naive subjects on emtric-itabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in Study GS-01-934. J Acquir Immune Defic Syndr. 2009;52(2):209–221.
   PubMed Web of Science ®Google Scholar
• Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 2006;3(9):e356.
   PubMed Web of Science ®Google Scholar
• Lima VD, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS. 2008;22(17):2371–2380.
   PubMed Web of Science ®Google Scholar
• Svicher V, Alteri C, Artese A, et al. Different evolution of genotypic resistance profiles to emtricitabine versus lami-vudine in tenofovir-containing regimens. J Acquir Immune Defic Syndr 2010;55(3):336–344.
   PubMed Web of Science ®Google Scholar
• White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002;46(11):3437–3446.
   PubMed Web of Science ®Google Scholar
• Miller MD, Margot N, Lu B, et al. Genotypic and pheno-typic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004;189(5):837–846.
   PubMed Web of Science ®Google Scholar
• Maserati R, De Silvestri A, Uglietti A, et al. Emerging muta-tions at virological failure of HAART combinations con-taining tenofovir and lamivudine or emtricitabine. AIDS. 2010;24:1013–1018.
   PubMed Web of Science ®Google Scholar
• Johnson MA, Gathe JC Jr, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr. 2006;42(2): 153–160.
   Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopi-navir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639):646–655.
   PubMed Web of Science ®Google Scholar
• Elion R, Cohen C, Ward D, et al. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. HIV Clin Trials. 2008;9(4):213–224.
   PubMed Web of Science ®Google Scholar
• Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22(12):1389–1397.
   PubMed Web of Science ®Google Scholar
• Walmsley S, Ruxrungtham K, Slim J, Ward D, Larson P, Raffi F. The Gemini Study: Saquinavir/r (SQV/r) vs lopinavir/r (LPV/r) plus emtricitabine/tenofovir (FTC/TDF) as initial therapy in HIV-1 infected patients [oral presen-tation PS1/4]. Paper presented at: 11th European AIDS Conference (EACS); October 24–27, 2007; Madrid, Spain.
   Google Scholar
• Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:1547–1556.
   PubMed Web of Science ®Google Scholar
• Frankel FA, Invernizzi CF, Oliveira M, Wainberg MA. Dimin-ished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. AIDS. 2007;21(6):665–675.
   PubMed Web of Science ®Google Scholar